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Tumor suppressor SMAR1 interacts and stabilizes p53 through phosphorylation at its serine-15 residue. We show that SMAR1
transcription is regulated by p53 through its response element present in the SMAR1 promoter. Upon Doxorubicin induced
DNA damage, acetylated p53 is recruited on SMAR1 promoter that allows activation of its transcription. Once SMAR1 is
induced, cell cycle arrest is observed that is correlated to increased phospho-ser-15-p53 and decreased p53 acetylation.
Further we demonstrate that SMAR1 expression is drastically reduced during advancement of human breast cancer. This was
correlated with defective p53 expression in breast cancer where acetylated p53 is sequestered into the heterochromatin region
and become inaccessible to activate SMAR1 promoter. In a recent report we have shown that SMAR1 represses Cyclin D1
transcription through recruitment of HDAC1 dependent repressor complex at the MAR site of Cyclin D1 promoter. Here we
show that downmodulation of SMAR1 in high grade breast carcinoma is correlated with upregulated Cyclin D1 expression. We
also established that SMAR1 inhibits tumor cell migration and metastases through inhibition of TGFb signaling and its
downstream target genes including cutl1 and various focal adhesion molecules. Thus, we report that SMAR1 plays a central
role in coordinating p53 and TGFb pathways in human breast cancer.
Citation: Singh K, Mogare D, Giridharagopalan RO, Gogiraju R, Pande G, et al (2007) p53 Target Gene SMAR1 Is Dysregulated in Breast Cancer: Its Role
in Cancer Cell Migration and Invasion. PLoS ONE 2(8): e660. doi:10.1371/journal.pone.0000660
INTRODUCTION
Nuclear matrix and matrix binding proteins maintain chromatin
architecture that is altered in cancer [1]. MAR (Matrix
Attachment Region) binding proteins (MARBPs) like p53, Ku,
PARP, SATB1, Cux/CDP are involved in regulation of various
physiological processes that include cell cycle progression, DNA
damage-repair, apoptosis etc. [2]. Among these MARBPs, p53 is
frequently mutated in more than 50% human cancer patients [3].
Some of these specific mutations allow p53 to bind to MAR
sequences with higher affinity, distort double strand DNA and thus
affect transcription [4]. DNA damage and other stress induce p53
mediated cell cycle arrest, apoptosis and cellular senescence
through post-translational modification of p53 like phosphoryla-
tion, acetylation, sumoylation etc. that play role in regulating the
stability and transcriptional activity of p53 [5–7]. Whereas N-
terminal phosphorylation is important for stabilization, C-terminal
acetylation regulates the DNA binding properties of p53 by
interfering with its nuclear import-export, degradation and
tetramerization [8]. Dual acetylation of p53 at K373/382 is
required for its transactivation function and transient or prolonged
acetylation decides the cell fate towards either cell cycle arrest or
apoptosis [9,10]. Other cell cycle regulatory proteins include
various Cyclins and Cyclin dependent kinase (cdk) complex that
are aberrantly expressed in cancer. Among all Cyclins, Cyclin D1
expression is one of the hallmarks of breast cancer progression and
is considered as a positive diagnostic marker [11,12]. Various
growth factors such as IGF I, IGF II, TGF-b, retinoic acid etc.
induce Cyclin D1 expression [13–16]. Apart from these growth
factors, oncogenic signals mediated by Ras, Src, Stats and Erb2 that
are involved in cellular transformation also activate Cyclin D1
[17,13,18,19].
Tumor growth and its metastatic potential are decided by the
growth factors available in the surrounding microenvironment.
One of the major cytokines, TGFb plays a dual role in breast
cancer by regulating both growth inhibitory and pro-migratory
signals in primary and advanced stages of breast cancer re-
spectively, as decided by the extent of Ras activity [20]. TGFb
signaling involves family of stress-activated kinases to exhibit its
effect [21]. Receptor activated Smad2 is phosphorylated upon
EGF activation by PKC and ERK [22,23]. Phosphorylated
Smad2 then oligomerizes with Smad4 and translocates into the
nucleus to further activate its target gene transcription [24,25].
Tumor metastasis is further enhanced by increased expression of
one of the major TGFb target gene CUTL1 [26]. Cux/CDP/
CUTL1 is another MAR binding protein, known to regulate
mammary specific gene transcription and breast tumorigenesis
[27]. CDP also regulate various developmental genes and affects
cell growth and differentiation [28].
SMAR1 was identified as a MAR binding protein from T cell
library through its direct binding to MARb sequence at TCRb
locus and affect V(D)J recombination as observed in SMAR1
transgenic mice [29,30]. SMAR1 also repress Eb mediated
transcription at TCRb via its interaction with Cux/CDP [31].
Interestingly, SMAR1 shows more than 99% identity with its
human counterpart BANP that has been precisely mapped to the
locus 16q24 [32]. Loss of heterozygosity (LOH) at this locus is
frequently reported in breast, colon and prostate cancer and is
correlated to Cyclin D1 deregulation [33–35]. This again
suggested that SMAR1 might have a role in breast tumorigenesis.
Academic Editor: Neil Hotchin, Birmingham University, United Kingdom
Received May 9, 2007; Accepted June 21, 2007; Published August 1, 2007
Copyright:  2007 Singh et al. This is an open-access article distributed under
the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the
original author and source are credited.
Funding: This work is supporter by National Centre for Cell Science (NCCS),
Department of Biotechnology (DBT), Department of Science and Technology
(DST) and Indian Council of Medical Research (ICMR), Government of India.
Competing Interests: The authors have declared that no competing interests
exist.
* To whom correspondence should be addressed. E-mail: samit@nccs.res.in
PLoS ONE | www.plosone.org 1 August 2007 | Issue 8 | e660
In a recent report we have shown that SMAR1 interacts with
HDAC1 associated repressor complex at Cyclin D1 promoter and
allows histone deacetylation to cause its transcriptional repression
[36]. Earlier, we have shown that SMAR1 is down modulated in
various transformed cell lines and can reduce the tumorigenic
potential of B16F1 through p53 stabilization [37,38]. However,
the regulation and role of SMAR1 in cell proliferation, cell
invasion and metastasis in human cancer patients is not known.
Here we show that SMAR1 expression is drastically reduced in
malignant Infiltrating Ductal Carcinomas (IDC) grade I, II and
III. Further we could establish that SMAR1 stabilizes p53 and thus
positively regulates p53 is itself transcriptionally regulated by p53.
Both in breast cancer cell lines and patient tissue samples
decreased SMAR1 expression was correlated with defective p53
expression pattern and increased Cyclin D1 levels. Thus, we propose
that mutant or defective p53 in breast cancer might result in
compromised SMAR1 expression. Microarray analysis carried out in
SMAR1 stable clone showed downregulation of various oncogenes,
Cyclins, focal-adhesion molecules, TGFb related genes and
upregulation of various growth inhibitory, DNA repair and stress
response genes. Interestingly, we found that SMAR1 overexpression
leads to reduced TGFb activation whereas SMAR1 expression was
reduced upon recombinant TGFb1 treatment. Further, stable
expression of SMAR1 was shown to inhibit the metastatic potential
of mouse melanoma cell line B16F1 in-vivo. Thus, we establish that
SMAR1, another MAR binding protein, cross-talks between p53
and TGFb signaling pathways and plays an important role in
regulating tumor growth and metastases in breast cancer.
RESULTS
SMAR1 is Downregulated in Breast Cancer
Human breast cancer samples were classified into fibro-adenoma
(FAB), lactating benign fibro-adenoma (LFAB), Infiltrating Ductal
Carcinoma Grade I, II and III (IDC G I, II and III) by standard
HE staining. Thirty fibro-adenoma benign cases (including
lactating benign fibro-adenoma) and thirty malignant cases
(including grade I, II and III) were used for SMAR1 expression
analysis. For comparison adjacent normal globular tissue area
were taken as normal control. Nuclear polymorphism and
hyperchromatasia was observed in all high-grade carcinoma
(Figure 1A and 1B). SMAR1 expression was significantly reduced
in all malignant IDC tissue samples as compared to either benign
or normal (Figure 1B). Interestingly, the expression of SMAR1 was
restricted to the cytoplasm in fibro-adenoma cases while it was
present in both nucleus and cytoplasm as observed in adjacent
normal tissue. SMAR1 expression was further correlated with
Cyclin D1 levels where an inverse staining pattern was observed
particularly in lactating benign fibro-adenoma. Whereas SMAR1
expression was observed in the outer layer of arrested epithelia,
Cyclin D1 was expressed in all proliferating cells but not in the
arrested epithelia (Figure 1C). SMAR1 was expressed in the early
stages of breast cancer and showed colocalization with p53.
Further, Cyclin D1 expression was higher in IDC grade III
samples, while SMAR1 staining was drastically reduced
(Figure 1D). Finally, Western blot analysis using whole protein
lysate of breast cancer tissues confirmed the downregulation of
SMAR1 and p53 along with upregulation of Cyclin D1
(Figure 1E). Further, quantitative analysis of SMAR1 staining in
all breast cancer samples has revealed upto 2.5, 5.8 and 11 fold
downregulation in mean fluorescence intensity (MFI) per 50 mm2
of the tissue area in IDC G-I, II and III as compared to the fibro-
adenoma benign (Figure 1F). These results suggested that SMAR1
is downmodulated during breast cancer progression, which might
be due to defective p53 function and as a consequence, Cyclin D1
expression is upregulated in the absence of its negative regulator
SMAR1.
SMAR1 Promoter Activity and Expression is p53
Dependent
Since, in advanced cases of breast cancer SMAR1 is deregulated,
we wanted to delineate the mechanism of SMAR1 regulation.
Gene map analysis showed that SMAR1 is located at human
chromosome 16q24.3 locus. This region harbors tumor suppressor
genes involved in breast cancers [33]. To further investigate the
endogenous regulation of SMAR1 transcription, promoter region
was identified and characterized using homology search tools and
Clustal W multiple sequence alignment. 1.1 kb putative promoter
sequence was identified and analyzed using Proscan. The TATA
box is located at 2655 along with MALT and GC box at 2585
and 2920 positions respectively. Transfac program predicted
various transcription factor-binding sites including AP-1, GATA-
1, CDP-CR, E2F etc. (Figure 2A). Along with these transcription
factor-binding sites, SMAR1 promoter also harbors other response
elements related to EGFR, TGFb and Cyclin D1 (data not
shown). Two fragments 0.95 kb and 1.5 kb immediate upstream
of the ATG, were cloned into luciferase reporter system and
promoter activities were analyzed. Upto 14 and 15 fold higher
promoter activity was observed within 0.9 kb region (Figure 2B
lane 2) and 1.5 kb promoter region (Figure 2B lane 3) respectively
as compared to the control (Figure 2B lane 1) in 293 indicating
that the maximum promoter activity resides within 0.95 kb region.
The antisense clones of the same regions did not show remarkable
promoter activity (Figure 2B lane 4 and 5). Interestingly, upstream
of TATA box there are two putative p53 response elements
present at 2369 and 2170 indicating a possible involvement of
p53 in SMAR1 transcription (Figure 2A). To check this, both
p532/2 or mutant cell lines were used. Compared to WT p53
containing cell lines (293 and MCF7), p53 null cell lines (H1299
and Hct116) showed negligible promoter activity. Interestingly, 8–
10 fold less promoter activity was observed both in MDA-MB-231
and MDA-MB-468 cell lines that express truncated and mutant
p53 (lysine 273) respectively compared to 293 cells (Figure 2C lane
2, 6 and 7). Also there was 2–3 fold downregulation of SMAR1
promoter activity in MDA-MB-231 and MDA-MB-468 cell lines
respectively as compared to MCF7 cells (Figure 2C lane 3, 6 and
7). These observations suggested that SMAR1 promoter activity is
dependent on functional p53.
Various stress signals causing DNA damage including many
chemotherapeutic drugs like Doxorubicin, Camptothecin are
known to activate p53 [39,40]. To investigate the requirement
of activated p53, Doxorubicin was used to induce p53 and
SMAR1 promoter activity was assayed in various cancer cell lines.
Doxorubicin treatment allowed induction of SMAR1 promoter
activity by 5 fold in 293 and 4 fold in MCF7 cells respectively
(Figure 3A and 3B). Further quantitative real time PCR analysis
revealed that upon 4 hr of Doxorubicin treatment there was 18.7
and 19.5 fold increase in SMAR1 transcript in 293 and MCF7
cells respectively (Figure 3C). This further supported p53
dependent regulation of endogenous SMAR1 expression. Doxo-
rubicin also induced SMAR1 protein expression as analyzed by
confocal microscopy and western blotting in 293 and MCF7 cells
respectively (Figure 3D and 3E). Similar results were observed in
B16F1 cells (data not shown). Interestingly, Doxorubicin treatment
failed to induce SMAR1 promoter activity both in p532/2 and
p53 mutant cell lines again confirming the requirement of active
p53 for SMAR1 promoter function. To test if the N terminal
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phosphorylation of Serine residues can affect the promoter
activity, two single amino acid p53 mutant constructs (ser15-ala
and ser20-ala) were transfected in p532/2 cell line. Both of the
mutant p53 constructs failed to rescue SMAR1 promoter activity
and its expression (data not shown). A significant restoration of
promoter activity was observed upon introduction of WT p53 in
the null cell lines H1299 and Hct116 (Figure 4A). Interestingly,
WT p53 failed to rescue the promoter activity in MDA-MB-231
and MDA-MB-468 cells, expressing mutant p53 (Figure 4B). Also
increasing dose of Doxorubicin did not induce endogenous
SMAR1 expression in p53 null as well as mutant cell lines (data
not shown). All These observations suggest that expression of WT
p53 is required for SMAR1 gene expression.
Recruitment of p53 at SMAR1 Promoter
Since SMAR1 promoter activity is dependent on p53 function, we
further analyzed the p53 response elements present in SMAR1
promoter. The sequence analysis showed two putative consensus
p53 binding sites at 2369 and 2170 present upstream of TATA
box (Figure 4C). To further investigate the p53 binding at these
Figure 1. SMAR1 is downregulated during advancement of breast cancer. (A) Breast cancer tissue samples grading by HE staining into Normal
Globular elements (NGE), Fibro-Adenoma Benign (FAB), Lactating Fibro-adenoma Benign (LFAB), Infiltrating Ductal Carcinoma Grade I- III (IDC G-I, II
and III). (B) Immuno-fluorescence confocal staining for SMAR1 in NGE, FAB, IDC G I, II and III breast tumor sample using rabbit polyclonal a-SMAR1
probed with FITC conjugated a-rabbit secondary antibody shown as green, counterstained with propidium iodide to stain nucleus as red. (C) SMAR1
and Cyclin D1 expression using rabbit a-SMAR1 and rabbit a-Cyclin D1 probed with FITC conjugated a-rabbit secondary antibody shown as green,
counterstained with propidium iodide to stain nucleus as red in Lactating Fibro-adenoma benign sample. (D) Expression analysis of SMAR1, Cyclin D1
and p53 in FAB and IDC G-III breast cancer sample by triple immuno-staining using rabbit a-SMAR1, mouse a-Cyclin D1 and goat a-p53 probed with
donkey a-rabbit FITC, donkey a-mouse Cy3 and donkey a-goat Cy5 (Sky blue) respectively. Nucleus was counterstained by DAPI. (E) Representative
Western blot showing the relative expression of SMAR1, Cyclin D1 and p53 in total protein lysate from fibro-adenoma (FAB) and IDC grade III tumor
tissue sample. (F) Mean fluorescence intensity of SMAR1 staining in thirty FAB, ten IDC G-I, ten IDC-G II and ten IDC-GIII breast cancer samples were
measured. Five different fields were taken for each sample and 6SD is indicated.
doi:10.1371/journal.pone.0000660.g001
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response elements, two amplified probes of 200 bp (Probe I) and
310 bp (Probe II) corresponding to proximal and distal p53 REs
were used for EMSA analysis. Binding assays were performed
using nuclear lysate from 293 and H1299 cells. A specific p53
complex-I was found with Probe I using cell lysate that has WT
p53 but not with the lysate from null cell line indicating that p53
directly binds to the probe I region. On the other hand, Probe II
that includes another p53 binding site with shorter linker did not
show p53 complex (Figure 4D). Distal p53 binding site was further
minimized to 52-mer oligo (probe III) containing consensus p53
binding site and 32-mer (probe IV) deletion mutants, and were
used as probe (Figure 4C). Sequence alignment of p53 RE (Probe
III) on SMAR1 promoter showed significant identity with the
consensus p53 binding site (Figure 4C). Upon adding increasing
amount of nuclear lysate of 293 cells Probe III showed increased
p53 complex, while probe IV failed to make any complex
(Figure 4D). Probe III did not show any complex either with the
nuclear lysate of p53 null cell lines (H1299, Hct116 and PC3) or
with p53 mutant cell lines (MDA-MB-231 and MDA-MB-468)
suggesting binding of WT but not mutant p53 (data not shown).
Since various post-translational modifications like phosphoryla-
tion, acetylation are known to affect p53 transactivation function,
we checked the status of both phosphorylated and acetylated p53
in context to SMAR1 expression. While p53 expression was
induced upto two fold in 4 hr, phospho-serine 15 was increased
after 8 hr of Doxorubicin treatment in 293 cells (Figure 4E). This
was then followed by increased SMAR1 transcription. Increased
phospho-p53 after 8 hr indicates SMAR1 induction and concom-
itant stabilization of p53 due to SMAR1. This observation again
confirmed our previous findings that SMAR1 overexpression leads
to p53 stabilization in the nucleus [38]. We then checked the status
of acetylated p53 upon Doxorubicin treatment and observed
increased acetylated p53 at K373/382 residues within 4 hr that
retained till 8 hr (Figure 4F). Since, acetylated p53 was reduced after
24 hr, we further checked whether SMAR1 could alter p53
acetylation. SMAR1 overexpression in 293 cells resulted in upto 3
fold decreased p53 acetylation (Figure 4G). To further investigate the
direct binding of total as well as acetylated p53 on SMAR1 promoter,
ChIP assays were performed. Both in Doxorubicin treated and
Figure 2. Identification and functional characterization of SMAR1 promoter. (A) SMAR1 promoter map showing various promoter elements with
transcription factor binding sites including p53. (B) SMAR1 promoter luciferase assay in 293 cells showing promoter activity of 1.5 kb or 0.95 kb sense
promoter constructs (lanes 2 and 3) respectively compared to the pGL3 vector control (lane 1). In addition 1.5 and 0.95 kb antisense SMAR1 promoter
constructs were used as negative control (lanes 4 and 5). (C) SMAR1 promoter luciferase assay in 293 (lane 2), MCF7 (lane 3), H1299 (lane 4), Hct116
(lane 5), MDA-MB-231 (lane 6) and MDA-MB-468 (lane 7) compared to pGL3 basic vector control (lane 1). Error bars indicate standard deviation.
Results shown are representative of at least five independent experiments.
doi:10.1371/journal.pone.0000660.g002
Figure 3. SMAR1 promoter activity is induced by Doxorubicin. (A and
B) SMAR1 promoter luciferase activity upon 0.25, 0.5, 0.75 and 1.0 mM
Doxorubicin (lane 3–6) compared to untreated cells (lane 2) and pGL3
basic vector control (lane 1) in 293 and MCF7 cell lines respectively.
Relative Luciferase units are represented and error bars indicate
standard deviation. Data is representative of three independent,
simultaneously performed experiments. (C) Real time PCR analysis for
SMAR1 in 0.5 mM Doxorubicin treated 293 and MCF7 cells respectively.
Relative expression of SMAR1 transcript is shown and error bars indicate
standard deviation. Data is representative of at least five independent
experiments. (D and E) Immuno-fluorescence confocal analysis and
Western blot analysis for SMAR1 in 0.5 mM Doxorubicin treated 293 and
MCF7 cells. Scale bar represents 10 mm.
doi:10.1371/journal.pone.0000660.g003
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Figure 4. SMAR1 transcription is regulated by p53 through its direct recruitment on SMAR1 promoter. (A and B) SMAR1 promoter luciferase assay
in H1299 (p53 null), Hct116 (p53 null) and MDA-MB-231 (p53 mutant), MDA-MB-468 (p53 mutant) cells (lane 2), SMAR1 promoter activity with 0.5 mM
Doxorubicin (lane 3), along with co-transfection of WT p53 without and with 0.5 mM Doxorubicin treatment (lane 4 and 5 respectively) compared to
pGL3 basic vector control (lane 1). Relative Luciferase units are represented along with error bars indicating standard deviation. Data is representative
of three independent, simultaneously performed experiments. (C) Schematic representation of p53 binding site on SMAR1 promoter, sequence of WT
p53 oligo (Probe III), deletion mutant oligo (Probe IV) and alignment of Probe III with p53 consensus binding site. Mismatches are given as bold. (D)
EMSA using H1299 and 293 nuclear lysate showing p53 dependent complex-I only with probe I and not with Probe II (first and second panel). EMSA
using 2.5, 5.0 and 10 mg of nuclear lysate from of 293 cells with probe-III and Probe IV (third and fourth panel). Complex-II came as non-specific signal.
(E and F) Western blot analysis for total, phospho-serine-15 p53 and acetylated p53 K373/382 upon 0.5 mM Doxorubicin treatment from 0–24 hr in
293 cells. (G) Western blot analysis for acetylated p53 K373/382 upon increasing amount of pBK-CMV-SMAR1 transfection as compared to vector
control in 293 cells. Relative fold change in expression is calculated by densitometric analysis normalized to the b-actin and are mentioned below
respective panel. (H) Recruitment of p53 on the 200 bp region (Probe I) of SMAR1 promoter. Sonicated DNA fragments were pulled with a-p53
antibody and PCR for the 200 bp region was performed in the pulled DNA fragments. Lane 1 is the input PCR, lane 2 is the isotype (IgG) control and
lane 3 is a-p53 pulled chromatin sample. (I) Recruitment of acetylated p53 and acetylated Histone-3 to the 200 bp region (Probe I) of SMAR1
promoter in the respective panels with and without Doxorubicin treatment. Input represent total sonicated genomic DNA, Isotype represents IgG
control and Immune represents the pulled chromatin fraction by a-acetylated p53 and a-acetylated Histone-3 antibodies respectively.
doi:10.1371/journal.pone.0000660.g004
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untreated samples, total p53 were bound to 200 bp promoter region
(Probe-I) of SMAR1 containing p53-binding site (Figure 4H).
Interestingly, acetylated p53 at K373/382 was bound only in
Doxorubicin treated samples (Figure 4I). Further using a-acetylated
Histone-3 (K9), we found that in Doxorubicin treated samples, core
Histone-3 was acetylated at lysine-9 (Figure 4I). Immunoprecipita-
tion of all the proteins was confirmed by probing the chromatin
pulled fraction with respective antibodies (Supplemetary Figure S1).
Thus, recruitment of acetylated p53 on SMAR1 promoter in
Doxorubicin treated samples resulted in its transcriptional activation
through facilitating the core Histone acetylation at the locus.
Earlier, we have shown that overexpression of SMAR1 leads to
cell cycle arrest [38,36]. Since, Doxorubicin results in cell cycle
arrest through activation of p53, we investigated the role of
SMAR1 in Doxorubicin mediated cell cycle arrest. Doxorubicin
treated 293 cells were subjected to FACS for cell cycle analysis. A
shift of 9%, 13% and 15% cell population was observed towards
G1/S phase after 8, 16 and 24 hr respectively in treated cells as
compared to untreated cells. After 36 and 48 hr, Doxorubicin
treated cells were arrested in G2/M phase. siRNA against
SMAR1 along with Doxorubicin treatment, reduced the in-
hibitory effect of Doxorubicin on cell cycle, confirming the direct
involvement of SMAR1 in Doxorubicin mediated cell cycle arrest
(Supplementary Figure S2 and Supplementary Table S1). We
further checked the status of various Cyclins like Cyclin D1, D3, A,
E and found that all these Cyclins were downregulated whereas
p27 level was increased upon Doxorubicin treatment. This
downregulation was correlated with SMAR1 upregulation (Figure
S3A). To further verify the contribution of SMAR1 in control of
these cell cycle regulatory proteins, siRNA against SMAR1 was
used in the presence of Doxorubicin. None of these Cyclins or p27
were affected by Doxorubicin in the absence of SMAR1 (Figure
S3B). In summary, above results suggest that p53 acetylation
caused by Doxorubicin activates SMAR1 promoter activity. The
induced SMAR1 expression is then correlated with increased p53
phosphorylation at serine-15 and decreased acetylation at lysine
373/282. Thus, SMAR1 and p53 positively regulate each other
where p53 activates SMAR1 transcription and SMAR1 stabilizes
p53. Further cell cycle arrest at G1/S or G2/M phase is observed
is correlated to induced SMAR1 expression and p53 stabilization.
SMAR1 also cause reduction in p53 acetylation and hence limits
p53 function to cause only cell cycle arrest and not apoptosis. In
addition, SMAR1 also modulated the expression of other cell cycle
regulatory proteins.
Figure 5. Localization of acetylated p53 in breast carcinoma. (A) Immuno-fluorescence confocal analysis for Ac-p53 in FAB and IDC G-III human
breast cancer sample shown by using Cy3 conjugated a-rabbit secondary antibody (red) and nucleus is counterstained by using DAPI (blue). White
arrows show accumulated acetylated p53 in the nucleolus (four respective magnified fields are shown as sub panels). (B) Immuno-fluorescence
confocal analysis for p53, Ac-p53 and Nucleolin in breast cancer cell lines MCF7, Hbl-100 and MDA-MB-231.
doi:10.1371/journal.pone.0000660.g005
Role of SMAR1 in Breast Cancer
PLoS ONE | www.plosone.org 6 August 2007 | Issue 8 | e660
SMAR1 Deregulation due to Altered Expression of
Acetylated p53
Since SMAR1 is downregulated in advanced breast cancer samples
and acetylated p53 is required for SMAR1 expression, we
investigated the status of acetylated p53 in various grades of breast
cancer samples by immuno-fluorescence. In benign tumor samples
acetylated p53 was observed both in nucleus as well as in nucleolus
whereas in the malignant samples, its levels were reduced and is
completely sequestered into the nucleolus, compared to benign
cases (Figure 5A). To support these results, we checked SMAR1,
total p53 and acetylated p53 in various breast carcinoma cell line
MCF7, Hbl-100 and MDA-MB-231 derived from breast epithelial
fibro-adenoma, breast epithelial milk cell and IDC G-III re-
spectively. Acetylated p53 at K373/382 was found both in
cytoplasm and nucleus in MCF7 whereas nuclear and nucleolar
expression were observed in Hbl-100 and MDA-MB-231 cells as
shown by its co-localization with Nucleolin (Figure 5B). Thus,
reduced SMAR1 expression in cell lines derived from IDC G-III
sample can be attributed to the altered compartmentalization of
mutant p53. Further, the phospho-serine-15 levels of p53 were
drastically downregulated in benign and malignant stages of breast
cancer (Figure S4A and B) implicating that once SMAR1 function
is disrupted, p53 is no more stabilized.
SMAR1 Inhibits Tumor Cell Migration and Invasion
To further examine the effect of SMAR1 on cell migration and
invasion, we employed three different tissue culture assays that
include wound healing assay, two chamber migration and two-
chamber Matrigel invasion assays. Poorly and highly metastatic
human breast cancer MCF7 and prostate cancer PC3 cell line
Figure 6. SMAR1 inhibits migration and invasion. (A and B) Two chamber migration and Matrigel invasion assay in MCF7, MDA-MB-231 and PC3
cells respectively. C refers to control cells and S refers to SMAR1 transfected cells. (C) Two-chamber invasion assay using SMAR1 stable and control
B16F1 cells. Total number of cells were counted in five different fields and given as per 100 mm2 area. Error bars represent standard deviation and
data is representative of three independent assays. (D) Time-Lapse image at the end of 10 hr in a wound-healing assay in control B16F1 cells. Few
representative tracks are superimposed above the cells to show their movement during wound healing. The left panel of the image shows a selection
of tracks of cell movement corresponding to the distance moved by the cells between 4th hr and 10th hr of time-lapse imaging. Bar 50 mM. (E and F)
represent time-lapse images and the selection of the tracks for B16F1 cells stably transfected with SMAR1 and siRNA to SMAR1 respectively, during
a wound-healing assay. The description of the image and the time points are similar to that of the control cells in (E). (G) Rate of migration of cells
during the wound healing analyzed from the time-lapse microscopy of B16F1 control indicated as C, SMAR1 stable indicated as S and siRNA treated
cells indicated as Si. Migration rate of at least 45 cells for each samples from five different fields were calculated. Error bars represent standard
deviation and data is representative of three independent experiments.
doi:10.1371/journal.pone.0000660.g006
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were used. In wound-healing assay, we observed that SMAR1
transiently transfected cells poorly migrated compared to control
cells (Figure S5A and S5B) Similarly, in two-chamber migration
assay, MCF7, PC3 and MDA-MB-231 cells showed 50, 11 and 3
fold reduction in number of cells migrated respectively (Figure 6A).
To further investigate the effect of SMAR1 on cell motility, Matrigel
coated chambers were used and invasiveness of MCF7, PC3 and
MDA-MB-231 cells were compared between vector transfected and
SMAR1 transfected cells. SMAR1 overexpressing cells showed
reduced invasion upto 3.5, 6 and 4.7 fold in MCF7, MDA-MB-231
and PC3 cell lines respectively (Figure 6B). Also SMAR1 stable clone
in B16F1 mouse melanoma cells showed 17 fold reduced invasion
compared to control B16F1 cells (Figure 6C). To further verify the
inhibitory effect of SMAR1 in cell migration, we performed real time
lapse video imaging assay in B16F1 SMAR1 stable clone and
SMAR1 siRNA treated B16F1 and compared the migration velocity
with respect to vector tranfected control B16F1 cells. Control B16F1
cells showed some movement towards the wound, though they did
not fill the wound gap completely (Figure 6D). B16F1 cells stably
transfected with SMAR1 showed only a little movement towards the
wound and did not fill the wound gap at all seen in the picture and in
the length of tracks (Figure 6E). B16F1 cells treated with siRNA for
SMAR1 filled the gap considerably, showed higher motility and
length of the cell tracks were longer compared to the control and
SMAR1 stable cells (Figure 6F).
In the analysis of single cell migration in a wound healing assay
SMAR1 stable clone showed almost 2 fold reduced and siRNA
treated cell showed 1.5 fold increased migration rate as compared
to the control cells (Figure 6G). For representative time-lapse video
images see Supplemental Videos (Video S1, S2 and S3). To further
verify the effect of SMAR1 expression in tumor metastases in-vivo,
experimental metastases assay was performed in nude mice. Tail
vein injection of SMAR1 stable and control cells showed 8.4 and
3.1 fold reduction in number of hepatic and splenic metastatic
colony formation respectively (Figure 7A). Representative HE-
stained tissue sections are given to show reduced colonization
(Figure 7B). In summary, our results show that tumor suppressor
SMAR1 causes inhibition of cell migration and invasion both ex-
vivo and in-vivo. SMAR1 has been identified as a chromatin
remodeling protein that controls gene expression by recruitment of
other co-factors [36]. We therefore checked the modulation of
specific genes by SMAR1 that are involved in migration and
cellular metastases.
SMAR1 Inhibits TGFb Signaling and CUTL1
Expression
Transforming growth factor beta (TGFb) has been earlier
implicated to play a major role in tumor metastases by increasing
expression of its downstream genes. Moreover, recently it has been
depicted that, CUTL1, a target gene of TGFb is highly expressed
in advanced breast cancer and in turn enhances tumor cell
metastases [26]. Since, SMAR1 is a global transcriptional
repressor that represses various cell cycle regulatory genes like
Cyclin D1, Cyclin D3, we suspected that SMAR1 might also affect
the expression of either TGFb or its downstream target gene
CUTL1. Further a detailed microarray analysis performed in
SMAR1 stable clone in B16F1 has shown significant down-
regulation in many oncogenes including Ras, Myc, Stat1, Fosb etc.
Various MAP-kinase signaling molecules were also downregu-
lated. Most of the Cyclins were reduced indicating the cell cycle
inhibitory role of SMAR1. Interestingly, we could also see
downregulation of TGFb related molecules including important
focal adhesion molecules like Vinculin, Fibronectin, ICAM5,
Cadherin 3, Integrin a5 etc. which play major role in cell
migration and motility whereas upregulation of tumor suppressor
genes and genes involved in cell cycle and DNA metabolism
(Tables 1 and 2). Most of these are TGFb target genes, suggesting
that SMAR1 might inhibit cellular migration and invasion by
modulating TGFb signaling.
Recently, CUTL1 another target gene of TGFb, is shown to
enhance tumor cell invasion and migration [26]. Thus, we
checked the relative expression of CUTL1, phospho-Smad2,
TGFb-R1, SMAR1 and p53 by immuno-fluorescence in SMAR1
stable clone in B16F1 and control cells and observed a significant
decrease in the expression of these proteins that correlated with
SMAR1 and p53 expression (Figure 8A). Further, in MCF7 cells
SMAR1 overexpression resulted in decreased TGFb-RI, phospho-
Smad2, Smad4 and increased Smad7 expression. Reversed effect
was observed in siRNA treated sample (Figure 8B). Interestingly,
we observed that CUTL1/CDP expression is drastically reduced
upon SMAR1 overexpression and increased upon SMAR1 siRNA
treatment (Figure 8B). SMAR1 expression was analyzed by real
time PCR in GFP-SMAR1 and siRNA transfected cells where 4.5
fold upregulation and 1.5 fold downregulation of SMAR1 was
observed in respective samples as compared to the mock-
transfected MCF7 cells (Figure 8C). These results also corroborate
Figure 7. SMAR1 inhibits metastases in-vivo. (A) Quantification of the hepatic and splenic colonization obtained with SMAR1 stable indicated as S
and B16F1 control cells indicated as C, 24 days post tail vein injection into nu/nu mice. Six nu/nu mice per sample were used for tail vein injection.
Average number of colonies per animal as observed in serial H&E sections of liver and spleen at a distance of 150 mM from each other are represented
along with 6SD of triplicate determinants. The assays were performed in triplicates. (B) Representative H&E staining showing hepatic and splenic
colonization of control and SMAR1 stable B16F1. The arrows in (B) indicate the colonies of control B16F1 cells in liver and spleen. Images were taken
at 20X magnification.
doi:10.1371/journal.pone.0000660.g007
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with the earlier report that Smad7 controls cell-cell interaction and
its overexpression inhibits breast cancer metastases [41]. Further
we checked the effect of SMAR1 upon Vinculin, Fibronectin,
Junctional adhesion molecule 2 (JAM2) expression and F-actin
organization. Vinculin associates with focal adhesion and aderens
junctions and promotes cell spreading and lamelllipodia formation
[42,43]. Fibronectin play vital role in maintaining the stability of
extracellular fibrils and favors adhesion dependent cell growth and
thereby enhance malignancy [44–46]. JAM2 a member of
junctional adhesion molecules family expression also promotes
cell migration [47,48] Interestingly we found that the expression of
Vinculin and JAM2 were decreased in SMAR1 stable clone in
B16F1 cells as compared to the control cells (Figure 8D). Also in
MCF7 cells treated with Doxorubicin for 48 hrs showed decreased
expression of Vinculin, Fibronectin and JAM2 (data not shown).
On the other hand SMAR1 siRNA treatment along with
Doxorubicin resulted in increased expression of these molecules
(data not shown). All these samples were also stained with Alexa
Fluor 488 phalloidin to look into the F-actin organization to
observe any cytoskeletal changes and found that the SMAR1
stable clone in B16F1 showed decreased F-actin expression
(Figure 8D). Also Doxorubicin treated MCF7 cells showed round
morphology instead of elongated with lowered F-actin expression
as compared to the untreated cells and siRNA treated cells
(Figure 8E). Since SMAR1 overexpression downmodulated TGFb
signaling and expression of its target gene CUTL1, we checked the
Table 1. Genes downregulated by SMAR1.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Annotation Fold change (log base 2) Gene symbol Description
Cell cycle
NM_007628 1.5 Ccna1 cyclin A1
NM_017367 1.2 Ccni cyclin I
NM_009833 1.0 Ccnt1 cyclin T1
NM_007635 1.1 Ccng2 cyclin G2
NM_007632 1.1 Ccnd3 cyclin D3
NM_133947 1.4 Numa1 nuclear mitotic apparatus protein 1
NM_009875 2.3 Cdkn1b cyclin-dependent kinase inhibitor 1B (P27)
Oncogenic signalling
NM_011785 2.1 Akt3 thymoma viral proto-oncogene 3
NM_008036 1.8 Fosb FBJ osteosarcoma oncogene B
NM_011952 1.2 Mapk3 mitogen activated protein kinase 3
NM_008416 1.8 Junb Jun-B oncogene
NM_010884 1.7 Ndrg1 N-myc downstream regulated gene 1
NM_013864 2.1 Ndrg2 N-myc downstream regulated gene 2
NM_016896 1.3 Map3k14 MAP kinase kinase kinase 14
NM_013931 1.3 Mapk8ip3 MAP kinase 8 interacting protein 3
NM_009101 2.0 Rras Harvey rat sarcoma oncogene, subgroup R
NM_009283 1.6 Stat1 signal transducer and activator of transcription 1
NM_011305 2.7 Rxra retinoid X receptor alpha
TGFb signalling
NM_009505 1.2 Vegfa vascular endothelial growth factor A
NM_008542 1.0 Smad6 MAD homolog 6 (Drosophila)
NM_019919 1.4 Ltbp1 latent TGFb binding protein 1
NM_025481 1.3 Smurf2 SMAD specific E3 ubiquitin protein ligase 2
Adhesion
NM_010233 1.2 Fn1 fibronectin 1
NM_015799 1.7 Trfr2 transferrin receptor 2
NM_011926 1.5 Ceacam1 CEA-related cell adhesion molecule 1
NM_010875 3.1 Ncam1 neural cell adhesion molecule 1
NM_009502 1.2 Vcl vinculin
NM_008319 1.5 Icam5 intercellular adhesion molecule 5, telencephalin
NM_010577 1.4 Itga5 integrin alpha 5 (fibronectin receptor alpha)
Others
NM_019743 1.6 Rybp RING1 and YY1 binding protein
NM_029083 1.5 Ddit4 DNA-damage-inducible transcript 4
NM_007602 2.1 Capn5 calpain 5
Genes downregulated in SMAR1 stable clone as compared to control B16F1.
doi:10.1371/journal.pone.0000660.t001..
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reverse effect of TGFb on SMAR1 expression. For this we treated
MCF7 cells with human recombinant protein TGFb1 and
checked the expression of SMAR1 by real time PCR. We found
drastic downregulation upto 50 fold in SMAR1 expression after
12 hrs of treatment (Figure 8F). Moreover a reverse correlation
was found between SMAR1 and secreted TGFb1 in benign and
malignant breast cancer sample (Figure 8G). All these observations
confirmed that SMAR1 negatively regulates cellular migration.
Thus, decreased SMAR1 expression and activated TGFb signaling
in malignant breast cancer contributes to promote invasiveness of
tumor cells.
DISCUSSION
MARBPs like CUTL1, SAF-A, SAF-B, p114, p53 etc. has been
shown to alter chromatin integrity and nuclear matrix architecture
that gets dysregulated in various cancers [1]. Smar1, located at
16q24.3 is a ubiquitously expressed MARBP. It is downregulated
in many transformed cell lines including breast carcinoma cell
lines MCF7, Hbl-100, MDA-MB-231, MDA-MB-468 etc. [36,38].
Based on these findings we investigated the status of SMAR1
expression in human breast cancer patient samples. We found that
SMAR1 expression is downmodulated in high-grade malignant
human breast carcinomas compared to the benign samples. This
was further correlated to the expression of Cyclin D1 that was
increased in high-grade breast cancer. Since the downmodulation
of SMAR1 in breast cancer was correlated to p53 and Cyclin D1
levels, we further investigated the mechanism of its regulation. To
study this, we identified and characterized the promoter of
SMAR1 located at human 16q24.3 locus. Along with other
important transcription factor binding sites like GATA-1, E2F,
AP-1, SP-1 etc. we identified two putative p53 binding motifs of
which one was shown to be functional. SMAR1 has been shown to
be involved in chromatin remodeling at TCRb locus during V(D)J
recombination [30]. Thus, we proposed that any stimulus that
triggers chromatin changes might affect SMAR1 expression.
Microarray analysis has also shown upregulation of DNA repair
genes in SMAR1 stable clone again suggesting its direct
involvement in processes related to DNA damage. Anticancer
drug Doxorubicin was therefore used as a DNA damaging agent
that acts through p53 activation and found that SMAR1 was
induced upon Doxorubicin treatment in the cells containing WT
but not mutant p53. Further WT p53 was shown to directly bind
to its site present in SMAR1 promoter and induce its activity
whereas mutant p53 failed to do so. Thus, while SMAR1 stabilizes
p53 through direct interaction and phosphorylation, its own
transcription is dependent on p53. Interestingly, we observed that
Doxorubicin allows p53 acetylation, the onset of which triggers
SMAR1 promoter firing (see model; Figure 9). In a time
dependent Western blot analysis we found that upon Doxorubicin
treatment, induction of p53 acetylation at K373/382 corresponds
with SMAR1 induction. Chromatin immunoprecipitation assays
showed that Doxorubicin induced DNA damage consequently
leads to the recruitment of acetylated p53 on SMAR1 promoter
and thus activate its transcription. Along with p53 acetylation,
recruitment of p53 dependent activator complex on SMAR1
promoter also resulted in H3-K9 acetylation indicative of active
chromatin at the locus. Once SMAR1 reaches a threshold
expression, it allows deacetylation of p53 as shown upon SMAR1
overexpression. Upregulation of acetylated p53 is followed by
induction in SMAR1 expression that is further correlated with the
cell cycle where the SMAR1 expression was highest during G1/S
phase. Prolonged treatment of Doxorubicin resulted in G2/M
arrest, which can be explained due to SMAR1 mediated
Table 2. Genes upregulated by SMAR1.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Annotation Fold change (log base 2) Gene symbol Description
Cell cycle
NM_008613 1.4 Mns1 meiosis-specific nuclear structural protein 1
NM_013481 1.0 Bop1 block of proliferation 1
NM_007691 1.0 Chek1 checkpoint kinase 1 homolog (S. pombe)
NM_011045 1.4 Pcna proliferating cell nuclear antigen
NM_018855 1.0 Gas8 growth arrest specific 8
Tumor suppressor
NM_009765 1.2 Brca2 breast cancer 2
NM_134092 1.1 Mtbp Mdm2, transformed 3T3 cell double minute p53BP
DNA metabolism
NM_001013026 1.0 Ttf2 transcription termination factor, RNA polymerase II
NM_022811 1.0 Paf53 polymerase (RNA) I associated factor 1
XM_125902 1.2 Rex3 exportin, tRNA
NM_012012 1.8 Exo1 exonuclease 1
NM_011234 1.0 Rad51 RAD51 homolog (S. cerevisiae)
Others
NM_008704 1.6 Nme1 expressed in non-metastatic cells 1, protein
NM_010494 1.0 Icam2 intercellular adhesion molecule 2
NM_023061 1.0 Mcam melanoma cell adhesion molecule
NM_010722 1.0 Lmnb2 lamin B2
NM_013559 1.0 Hsp105 heat shock protein 105
Genes upregulated in SMAR1 stable clone as compared to control B16F1.
doi:10.1371/journal.pone.0000660.t002..
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stabilization of p53 in the nucleus. siRNA treatment of SMAR1
inhibited Doxorubicin mediated cell cycle arrest. Cell cycle
progression is thus regulated by p53 in response to DNA damage
through regulation of SMAR1 expression that is directly involved
in chromatin remodeling at the Cyclin D1 promoter loci. This
suggests that SMAR1 functions in synergism with the Doxorubicin
by conferring selective repressor activity to p53 through its
deacetylation that results only in cell cycle arrest and not
Figure 8. SMAR1 downregulates TGFb signaling. (A) Immuno-fluorescence confocal analysis for CUTL1, TGFb-R1, phospho-smad2, SMAR1 and p53
in SMAR1 stable clone and control B16F1 cells. (B) Western blot analysis for SMAR1, TGFb-R1, phospho-smad2, Smad 4, Smad7 and CUTL1 in siRNA
treated and SMAR1 transfected MCF7 cells compared to control cells. (C) Real time PCR for SMAR1 in MCF7 cells transfected with SMAR1 and in siRNA
treated cells compared to control cells. Fold change are represented with6SD of three independent experiments. (D) Immuno-flourescence confocal
analysis for Vinculin and JAM2 in SMAR1 stable clone in B16F1 and control cells. (E) Alexa Fluor 488 phalloidin staining in MCF7 cells treated with
Doxorubicin (0.5 mM) and siRNA for SMAR1 (100 nM) for 48 hr. (F) Real time PCR analysis for SMAR1 in MCF7 treated with human recombinant TGFb1
(10 ng/ml) for 0–12 hr. Relative expression of SMAR1 is shown with 6SD of three independent experiments. (G) Immuno-fluorescence confocal
analysis for secreted TGFb1 in human benign and malignant breast cancer tissue sample.
doi:10.1371/journal.pone.0000660.g008
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apoptosis. Thus, in addition to previously reported pathways [49]
here we report a new positive feedback regulation between p53
and SMAR1 where SMAR1 is transcriptionally activated by p53
and that in turn stabilize p53 by facilitating phosphorylation at
serine 15 residue.
The expression of SMAR1 is drastically downregulated during
breast cancer progression and is inversely correlated with Cyclin
D1 expression. Interestingly, we observed that acetylated p53 at
K373/382 showed diffused expression in the nuclear spaces with
higher expression in the nucleolar compartments in breast fibro-
adenoma and exclusively nucleolar translocation in IDC G-III
samples. These observations suggest that mutations in p53 may
lead to its altered status and expression pattern in human breast
carcinoma and is associated with its sequestration into hetero-
chromatin resulting in its compromised activity. Similar correla-
tion between p53 localization was observed in various breast
carcinoma cell lines where p53 and acetylated p53 were
predominantly present in the heterochromatin regions. All above
observations suggest a possible mechanism of SMAR1 dysregula-
tion in breast cancer due to abnormal p53 acetylation,
phosphorylation and its sub-cellular sequestration.
Moreover, SMAR1 leads to reduced migration and invasion in
both poorly and highly metastatic breast carcinoma cell lines
irrespective of p53 status in both transient and stably SMAR1
transfected cells through downregulation of TGFb signaling and
its target gene expression including CUTL1. Earlier we have
reported that SMAR1 inhibits ERK phosphorylation [37] that
may contribute to decreased phospho-Smad2 levels and thus
inhibits TGFb signaling. SMAR1 is also able to reduce metastatic
potential of B16F1 cells in-vivo in mice model. Microarray analysis
done in SMAR1 stable clone, showing downregulation of various
oncogenes, Cyclins, focal-adhesion molecules, TGFb related genes
and upregulation of various growth inhibitory, DNA repair and
stress response genes also indicated anti-tumorigenic and anti-
metastatic function of SMAR1. Our results establish SMAR1, as
a critical regulator of TGFb signaling cascade that finally affect
CUTL1 expression. Downregulation of SMAR1 in high-grade
breast carcinoma can be directly correlated with activated TGFb
signaling and its downstream target genes that consequently lead
to increased tumor metastasis. Thus, we propose that SMAR1 acts
as a key regulator of two major physiological processes of cellular
proliferation and metastases in breast cancer by interplaying
between p53 and TGFb pathway and thereby prevent tumor cells
to proliferate and metastasize (Figure 9).
In brief, we report SMAR1 as a transcriptional target of p53.
Increased SMAR1 expression in turn results in p53 stabilization.
Earlier PTEN-Akt, p14/19 ARF and Rb are reported to positively
regulated p53 [49], here we report another protein SMAR1 that
can also regulate p53 via positive feed forward loop. SMAR1 is
downregulated in advanced breast carcinoma stages due to
deregulated p53 function that again correlates with the elevated
Cyclin D1 expression. Moreover, SMAR1 overexpression in both
poorly and highly metastatic breast carcinoma cell lines leads to
reduced migration and invasion irrespective of p53 status
suggesting that the effect of SMAR1 in regulating genes involved
in tumor migration and invasion is downstream of p53 although
the wild type expression of SMAR1 is regulated by p53.
Doxorubicin mediated upregulation of SMAR1 is p53 dependent
and thus it does not function as efficiently in p53 mutated or null
breast cancer cell line. Reduced migration and invasion observed
in SMAR1 overexpressing cells were thus correlated to down-
regulated TGFb signaling and inhibition of downstream kinase
phosphorylation namely Smad2 phosphorylation. Further, various
TGFb target genes were observed to be downregulated such as
cutl1 that promote tumor cell metastases [26]. SMAR1 also
inhibited the expression of Fibronectin, Vinculin and JAM2 that
are involved in promoting cell-extracellular matrix adhesion, cell
spreading and migration [42–48], suggesting that SMAR1 might
Figure 9. Model showing the regulation of SMAR1 by p53 upon Doxorubicin treatment and its implication in cell proliferation, migration and
metastases.
doi:10.1371/journal.pone.0000660.g009
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prevent tumor cell metastases through negative regulation of these
proteins. Thus, SMAR1 is an important anti-tumorigenic protein
that regulates cell growth and metastases in breast cancer and acts
as a connecting link between p53 and TGFb pathway preventing
tumor cells to proliferate and metastasize.
MATERIALS AND METHODS
Mammalian cell culture and transfection
All cell lines were obtained from ATCC except Hct116 p532/2
and H1299 p532/2 cells that were obtained as kind gift from Dr.
Kumar Somasundaram (Indian Institute of Science, Bangalore,
India). Breast cancer cell line MCF7, Hbl100, mouse melanoma
cell line B16F1, SMAR1 stable clone [38], Hct116 p532/2,
H1299 p532/2 and human kidney embryonic cell line 293 were
maintained in DMEM supplemented with 10% fetal calf serum
(Invitrogen) in the presence of 5% CO2 at 37uC. MDA-MB-231,
MDA-MB-468 cells were maintained in L15 media (Invitrogen)
and PC3 cell lines were cultured Ham’s F12 media (Invitrogen)
supplemented with 10% fetal calf serum (Invitrogen) in presence of
5% CO2 at 37uC. Cells were seeded at a density of 1610
6 per
30 mm dish and cultured for 24 hr before transfection. One
microgram of pEGFP-vector or 1 mg of pEGFP-SMAR1 plasmid
DNA were used for transfection using Lipofectamine 2000,
following manufacturers protocol (Invitrogen). For Luciferase
promoter assays, SMAR1 promoter construct and pEGFP-p53
were used for transfection.
Plasmids and siRNA
pBK-CMV-SMAR1 and GFP-SMAR1 expression constructs
were used to overexpress SMAR1. Following siRNA specific for
SMAR1 (Ambion, Austin, TX): 59-UAACCCUGAGAUGCGG-
GUA with scrambled control RNA 59-UACCGUAGGCAUG-
CAAUGG at 100 pM concentrations for 48 hr, with a pre-
treatment of 8 hr, was used to knock-down SMAR1 [37].
SMAR1 promoter cloning and luciferase reporter
assay
SMAR1 promoter sequence was identified and characterized
using BLAST, Pro-Scan and Clustal W analysis. 950 bp promoter
sequence was amplified from human genomic DNA using the
following primer 59-ATGATGTAGTTCCTGGGGTTTGA-39
and 59-CTGCGATAATGGCGTCCGTC-39 (Genomechanix,
USA) and was cloned in Luciferase reporter vector pGL3 basic
via subcloning in pGMT-easy and pSP72 vector (Promega).
Utilizing an internal PvuII restriction enzyme site orientation of
promoter was checked and both sense and antisense constructs
were selected for further experiments. SMAR1 promoter construct
(0.5–2.0 mg/ml) was transfected with or without Doxorubicin
(0.5 uM) treatment in p53 wild type cell lines. One microgram of
GFP-p53, p53 Serine-15-Alanine and p53 Serine 20-Alanine
plasmid constructs were used to express WT or single amino acid
mutant p53 in p53 null cell lines with or without Doxorubicin
(0.5 mM) treatment. Cells were harvested after 24 hr post trans-
fection and/or treatment and were subjected to Dual Luciferase
assay as per manufacturer’s instruction (Promega). Luciferase
activity was measured using Fluoroskan Ascent Luminometer (Lab
Systems). All the assays were done in triplicates.
Reverse Transcriptase and Real-Time PCR
26105 cells treated with Doxorubicin (0.2–1.0 mM; Sigma) or
human recombinant TGFb1 (10 ng/ml; Sigma) for 0–12 hours
were harvested and total RNA isolated was subjected to cDNA
synthesis following the manufacturer’s instruction (Invitrogen).
PCR was done using specific primers for SMAR1 F-59-GCA-
TTGAGGCCAAGCTGAAAGCTC-39 and R-59-CGGAGTT-
CAGGGTGATGAGTGTGAC-39. b-actin was amplified using
following primers F-59-TACCACTGGCATCGTGATGGACT-
39 and R-59-TTTCTGCATCCTGTCGGAAAT-39, as a loading
control. Real time RT-PCR was performed by icycler iQ thermal
cycler system (Biorad) using double stranded DNA specific
flurophore SYBR Green (BioRad) as per our published protocol
[36]. Quantitation was performed with three different sets of
cDNA samples. Graphs were plotted and statistical analysis was
done using Sigma Plot.
Immunoblotting and antibodies
Cells were scraped, washed with 16PBS in different time intervals
and lysed in DIGNAM buffer. Protein concentrations were
estimated using Bradford reagent (Biorad). Equal amount of
protein was loaded for immunoblotting. Following SDS-PAGE,
resolved proteins were electroblotted on PVDF membrane
(Amersham). The membrane was blocked overnight in TBS
containing 0.1% Tween- 20 (TBST) and 10% BSA. The
membrane was then probed with primary antibody in TBST for
2 hrs at RT or overnight at 4uC followed by three 10 min TBST
washes at room temperature. Incubation with the secondary
antibody was done for 1 hr, three 10 min TBST washes were
given prior to chemiluminiscence detection using ECL substrate
(Amersham). All antibodies for Western blots were obtained from
Santa Cruz. Polyclonal rabbit antiserum was raised against
recombinant GST-SMAR1 truncated (400–548 aa) fusion protein
[37]. Mouse a-Cyclin D1, rabbit a-p27, TGFb1, TGFbRI,
phospho-Smad2 were procured from Cell Signaling and rabbit
a-acetylated p53-K373/382 from Upstate Signaling. Secondary
antibodies, goat a-mouse-HRP and goat a-rabbit HRP were
purchased from Biorad.
Immuno-flourescence
For Immunostaining 16105 cells were plated on coverslips and
immunostained for SMAR1 using rabbit polyclonal a-SMAR1
and detected with secondary antibody mix containing FITC-
conjugated a-rabbit IgG antibody (Bangalore Genei) following the
standard protocol [37]. F-actin staining was done using Alexa
Fluor 488 conjugated phalloidin (1U/ml; Molecular Probes,
Invitrogen). Breast carcinoma tissues were obtained from KEM
Hospital, Pune and Armed Force Medical College (AFMC, Pune).
Histological grading of tumor tissues was done following modified
Bloom and Richardson guidelines [50]. Immunoflourescence
staining was carried out after de-parafinization by heating at
60uC for 5 minutes followed by partial rehydration in 100% and
95% ethanol. Antigen retrieval was done by boiling in 0.01 M
citric acid. BSA blocked sections were stained with respective
primary antibodies and detected by donkey a-Rabbit-FITC
(Bangalore Genei), donkey a-Mouse Cy3 (Chemicon) and donkey
a-Goat Cy5 (Chemicon) secondary antibodies. Nucleus was
stained with Propidium Iodide (Sigma) or DAPI (Sigma). Sections
and coverslides were mounted in anti-fade mountant medium
(Sigma) and analyzed by Confocal laser microscope (LSM 510
version 2.01; Ziess, Thornwood, NY).
Enzyme mobility shift assay
For EMSA, probes were PCR labeled using a32p dCTP in a 25 ml
PCR reaction. For amplification of 2369 to 2569 (Probe I)
primers used were (For 59-TGCTGGGATTAAAGGTGTGC-39,
Rev 59-CCTGTTTCCTGCCCGTTCCC-39) and 2170 to
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2480 (Probe II) primers used were (For 59-GGGAACGGGCAG-
GAAACAG-39, Rev 59-TTCCGGGCTCGTTCAGTGGC-39).
PCR products were then eluted from native polyacrylamide gel by
phenol-chloroform method and subsequent precipitation by 70%
ethanol. Oligonucleotide labeling was done by klenowing reaction
using a32 p dCTP in a 20 ml reaction containing 25 mM dATG
mix, Klenow buffer and 0.5 U of Klenow (Invitrogen). Probe
purification was done using Probequant G 50 column (Amer-
sham). Binding reactions were performed in a 10 ml total volume
containing 10 mM Tris (pH 7.5), 1 mM DTT, 50 mM KCl,
50 mM NaCl, 5 mM MgCl2, 5% glycerol, 1 mg double stranded
poly (dI-dC), 10 mg BSA and 10 mg of nuclear lysate. Samples
were incubated for 5 min at room temperature prior to addition of
radiolabelled probe. Then the samples were incubated for 15 min
at room temperature, the products of binding reactions were
resolved by 8% native polyacrylamide gel electrophoresis. The gels
were dried under vacuum and processed for autoradiography.
Chromatin immunoprecipitation assays
Chromatin immunoprecipitation (ChIP) assays were performed
using Chromatin Immunoprecipitation assay kit (Upstate Bio-
technology) following manufacturer’s instructions. 16106 cells
were plated per 30 mm dish and treated with 0.5 uM Doxorubicin
for 6 hrs. After treatments, DNA-protein interactions were fixed
with 1% formaldehyde at 37uC for 10 min. ChIP assays were
carried out using a-p53, (Santa Cruz) a-Ac-p53-K372/383
(Upstate Signaling) and a-H3K9 (Cell Signaling) antibodies. Input
DNA, Rabbit IgG (r-IgG), and Mouse IgG (m-IgG) pulled DNA
served as controls for all the experiments. DNA immunoprecipi-
tated was then subjected to 35 cycles of PCR using primers for
probe I. Amplified PCR products were analysed by native PAGE
(10% Poly acrylamide gel) and ethidium bromide staining.
Wound healing, migration and invasion assays
An artificial wound was made using a 10 ml pipette tip on
confluent cell monolayers of vector or GFP-SMAR1 transfected
cells, after 8 hr serum starvation and cell migration was observed
in serum containing medium. Images were taken using Motorized
IX-81 inverted microscope attached with DP70 CCD camera
(Olympus). The number of cells migrated towards the wound was
calculated per 105 mm2 wound area after 12 hr. Cell migration
and invasion were determined by using the modified two-chamber
migration/invasion assay (8 mm pore size membrane uncoated/
coated with Matrigel, BD Biosciences) according to the manu-
facture’s instructions. 26105 cells were seeded in serum free media
on the upper migration/invasion chamber and were incubated in
the lower chamber containing media supplemented with 10%
serum for 24 hrs in humidified tissue culture incubator, at 37uC,
5% CO2. After 24 hrs, cells from the upper chamber were
removed by scrubbing and the migrated/invaded cells in the lower
chamber were fixed and stained with 100% methanol and 1%
Toluidine Blue respectively. Quantification was performed by
counting the number of stained cells per 100 mm2 area migrated/
invaded to the lower chamber.
Time-lapse video microscopy
Time-lapse imaging of migrating cells in wound healing assay was
performed on an Axiovert 200M microscope (Carl Zeiss,
Germany) over 10 hr in serum containing medium in humidified
chamber at 37uC and 5% CO2 atmosphere. Images were obtained
every 2 min using a 106phase objective of NA 0.25 and analyzed
using image analysis software Metamorph Universal Imagi-
ng,USA. A minimum of 45 cells per sample were tracked to get
the total distance traveled over a time period of 10 hr time period.
The average migration speed in mm/hr was calculated and graphs
were plotted using Microsoft Excel and Sigma plot program.
In-vivo metastases assay
Male MNRI nu/nu mice (6 mice/group) were injected with 106
B16F1 control or B16F1 stably expressing SMAR1 cells/0.1 ml
PBS into the tail vain. Mice were sacrificed after 24 days post
injection and serial sections of the liver and spleen cut at the
distance of 150 mm from each other were hematoxylin-eosin (HE)
stained. The number of hepatic and splenic colonies was counted
in 15 sections per liver and spleen.
Microarray analysis
Microarray experiment was commercially done by Agilant
Genotypic Technology, Bangalore, India. Significantly regulated
genes are presented with the fold.0.5 for downregulation and.1
for upregulation between the mean expression values of B16F1
control and SMAR1 stable clones in triplicate experiments.
SUPPORTING INFORMATION
Figure S1 Western blot analysis for total p53, Ac-p53 (K372/
383), Ac-Histone 3 (K9) in chromatin immunoprecipitated
fractions of Doxorubicin treated and untreated 293 cell lysate
showing the respective immunoprecipitated proteins.
Found at: doi:10.1371/journal.pone.0000660.s001 (8.88 MB TIF)
Figure S2 Cell cycle analysis by FACS. 293 cells were treated
with Doxorubicin with or without SMAR1 siRNA for 0–48 hrs as
mentioned in the figure. Percent population in G1, S and G2
phase are represented as M1, M2 and M3 markers. The result
shown is representative of five independent experiments.
Found at: doi:10.1371/journal.pone.0000660.s002 (6.00 MB TIF)
Figure S3 Western blot analysis for Cyclin D3, p27, Cyclin D1,
Cyclin E, Cyclin A with b-actin as loading control in synchronized
293 cells upon 0.5 mM treatment of Doxorubicin with or with out
SMAR1 siRNA (100 nM) after various time points corresponding
to the FACS samples(A and B).
Found at: doi:10.1371/journal.pone.0000660.s003 (10.44 MB
TIF)
Figure S4 Immuno-fluorescence confocal analysis for phosphor-
serine 15 p53 using rabbit polyclonal a-p53 ser-15 primary
antibody and was detected by goat a-rabbit-Cy3 secondary
antibody in Fibroadenoma (A) and Infiltrating Ductal Carcinoma
grade III (B) breast cancer sample. DAPI was used to counter stain
nucleus.
Found at: doi:10.1371/journal.pone.0000660.s004 (7.71 MB TIF)
Figure S5 Wound healing assay in control MCF7 (A) and PC3
cells (B) or in cells transiently transfected with SMAR1. Images
represent control cells and SMAR1 siRNA transfected cells at 0 hr
and after 24 hr of transfection.
Found at: doi:10.1371/journal.pone.0000660.s005 (7.66 MB TIF)
Table S1 Percent population shift towards G1/S and G2/M
phase in Doxorubicin (0.5 mM) treated with and without siRNA
(100 nM) compared to control untreated synchronized 293 cells.
Found at: doi:10.1371/journal.pone.0000660.s006 (0.03 MB
DOC)
Video S1 Time lapse video showing migration of control B16F1
cells.
Found at: doi:10.1371/journal.pone.0000660.s007 (1.61 MB
MOV)
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Video S2 Time lapse video showing migration of SMAR1 stable
B16F1 cells.
Found at: doi:10.1371/journal.pone.0000660.s008 (1.62 MB
MOV)
Video S3 Time lapse video showing migration of SMAR1
siRNA treated B16F1 cells.
Found at: doi:10.1371/journal.pone.0000660.s009 (1.60 MB
MOV)
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